 | • レポートコード：MRC2305B056 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、248ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のホルモン避妊薬市場規模が2021年に151.4億ドル、2022年に161.2億ドルとなり、今後年平均6.66％拡大して2027年には223.0億ドルまで成長すると予測しています。当市場調査レポートは、ホルモン避妊薬の世界市場を多面的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、ホルモン種類別（アンドロゲン、抗アンドロゲン剤、エストロゲン、ゴナドトロピン、プロゲストーゲン）分析、方法別（混合経口避妊薬、埋め込み型避妊薬、注入型避妊薬、子宮内避妊薬、経皮パッチ）分析、エンドユーザー別（外来手術センター、婦人科センター、在宅医療、病院＆クリニック）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめました。また、当書には、AbbVie Inc.、Afaxys, Inc、Agile Therapeutics、Amgen Inc.、Ansell Ltd、Apothecus Pharmaceutical Corporation、Bayer AG、BioSante Pharmaceuticals Inc.、Boehringer Ingelheim GmbH、Church & Dwight, Co., Inc.、Cipla Limitedなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のホルモン避妊薬市場規模：ホルモン種類別 - アンドロゲンの市場規模 - 抗アンドロゲン剤の市場規模 - エストロゲンの市場規模 - ゴナドトロピンの市場規模 - プロゲストーゲンの市場規模 ・世界のホルモン避妊薬市場規模：方法別 - 混合経口避妊薬の市場規模 - 埋め込み型避妊薬の市場規模 - 注入型避妊薬の市場規模 - 子宮内避妊薬の市場規模 - 経皮パッチの市場規模 ・世界のホルモン避妊薬市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - 婦人科センターにおける市場規模 - 在宅医療における市場規模 - 病院＆クリニックにおける市場規模 ・世界のホルモン避妊薬市場規模：地域別 - 南北アメリカのホルモン避妊薬市場規模 アメリカのホルモン避妊薬市場規模 カナダのホルモン避妊薬市場規模 ブラジルのホルモン避妊薬市場規模 ... - アジア太平洋のホルモン避妊薬市場規模 日本のホルモン避妊薬市場規模 中国のホルモン避妊薬市場規模 インドのホルモン避妊薬市場規模 韓国のホルモン避妊薬市場規模 台湾のホルモン避妊薬市場規模 ... - ヨーロッパ/中東/アフリカのホルモン避妊薬市場規模 イギリスのホルモン避妊薬市場規模 ドイツのホルモン避妊薬市場規模 フランスのホルモン避妊薬市場規模 ロシアのホルモン避妊薬市場規模 ... - その他地域のホルモン避妊薬市場規模 ・競争状況 ・企業情報 |
The Global Hormonal Contraceptives Market size was estimated at USD 15.14 billion in 2021 and expected to reach USD 16.12 billion in 2022, and is projected to grow at a CAGR 6.66% to reach USD 22.30 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Hormonal Contraceptives to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Hormone Type, the market was studied across Androgens, Antiandrogens, Estrogens, Gonadotropins, and Progestogens.
Based on Method Type, the market was studied across Combined Oral Contraceptives, Implanted Contraceptives, Injected Contraceptives, Intrauterine, Oral Contraceptives, Transdermal Patch, and Vaginal Ring.
Based on End-user, the market was studied across Ambulatory Surgical Centers, Gynecology Centers, Homecare, and Hospitals & Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Hormonal Contraceptives market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hormonal Contraceptives Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hormonal Contraceptives Market, including AbbVie Inc., Afaxys, Inc, Agile Therapeutics, Amgen Inc., Ansell Ltd, Apothecus Pharmaceutical Corporation, Bayer AG, BioSante Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Church & Dwight, Co., Inc., Cipla Limited, Covetrus, Inc., Glenmark Pharmaceuticals, HLL Lifecare Limited, Johnson & Johnson Services, Inc, Lupin Pharmaceuticals, Inc., Mayer Laboratories, Inc, Merck & Co. Inc., Mylan N.V, Novartis International AG, Pfizer, Inc., Piramal Healthcare Limited, Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Vardhman Life Care Pvt. Ltd., and Warner Chilcott Company.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Hormonal Contraceptives Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hormonal Contraceptives Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hormonal Contraceptives Market?
4. What is the competitive strategic window for opportunities in the Global Hormonal Contraceptives Market?
5. What are the technology trends and regulatory frameworks in the Global Hormonal Contraceptives Market?
6. What is the market share of the leading vendors in the Global Hormonal Contraceptives Market?
7. What modes and strategic moves are considered suitable for entering the Global Hormonal Contraceptives Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing awareness about the benefits and use of contraceptives
5.1.1.2. Government initiatives to promote the use of contraceptives
5.1.1.3. Need for oral contraceptives as a preferred method to avoid unplanned pregnancy
5.1.2. Restraints
5.1.2.1. Growing use of biologics instead of traditional chemical drugs
5.1.3. Opportunities
5.1.3.1. Increasing demand for a healthy life in emerging economies
5.1.3.2. Technological advancements in contraceptive methods
5.1.4. Challenges
5.1.4.1. Limited social acceptance
5.2. Cumulative Impact of COVID-19
6. Hormonal Contraceptives Market, by Hormone Type
6.1. Introduction
6.2. Androgens
6.3. Antiandrogens
6.4. Estrogens
6.5. Gonadotropins
6.6. Progestogens
7. Hormonal Contraceptives Market, by Method Type
7.1. Introduction
7.2. Combined Oral Contraceptives
7.3. Implanted Contraceptives
7.4. Injected Contraceptives
7.5. Intrauterine
7.6. Oral Contraceptives
7.7. Transdermal Patch
7.8. Vaginal Ring
8. Hormonal Contraceptives Market, by End-user
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Gynecology Centers
8.4. Homecare
8.5. Hospitals & Clinics
9. Americas Hormonal Contraceptives Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hormonal Contraceptives Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hormonal Contraceptives Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Afaxys, Inc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Agile Therapeutics
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Amgen Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Ansell Ltd
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Apothecus Pharmaceutical Corporation
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bayer AG
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. BioSante Pharmaceuticals Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Boehringer Ingelheim GmbH
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Church & Dwight, Co., Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Cipla Limited
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Covetrus, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Glenmark Pharmaceuticals
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. HLL Lifecare Limited
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Johnson & Johnson Services, Inc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Lupin Pharmaceuticals, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mayer Laboratories, Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Merck & Co. Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Mylan N.V
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Novartis International AG
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Pfizer, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Piramal Healthcare Limited
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Reckitt Benckiser Group PLC
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Sun Pharmaceutical Industries Ltd.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Teva Pharmaceutical Industries
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Vardhman Life Care Pvt. Ltd.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Warner Chilcott Company
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing